Psychedelics
Numinus Announces Listing of Warrants
Numinus Wellness Inc. (“Numinus” or the “Company“) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to announce that the TSX Venture Exchange (“TSXV“) has accepted for listing the 12,683,925 warrants (the “Warrants“) issued pursuant to the Company’s previously […]
Mydecine Innovations Group Included in First-Ever Psychedelics ETF
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has been included in the first-ever Psychedelics Exchanged Traded Fund (ETF). The Horizons Psychedelic Stock Index ETF index, which was announced […]
Entheon Biomedical to be Included in First North American Psychedelic ETF
Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) (“Entheon”), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce its inclusion in the Horizon North American Psychedelic ETF, the first ever psychedelic ETF of its kind. The new ETF is expected to start trading January 26, 2021 under […]
Revive Therapeutics Included in First Psychedelic Exchange Traded Fund
Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it is one of the seventeen companies in the U.S. and Canada that will be included in the First Psychedelics Exchange Traded Fund, […]
Mind Cure Health Inc. Announces an Increase to Previously Announced Bought Deal Public Offering
Mind Cure Health Inc. (“Mind Cure”) (CSE: MCUR), a mental health and wellness company with a mission to identify and develop products that ease suffering, increase productivity, and enhance mental health, is pleased to announce that it has entered into an amended agreement with a syndicate of underwriters led by Canaccord Genuity Corp. to increase […]
Havn Life Sciences Announces Inclusion in First Psychedelic Exchange Traded Fund
VANCOUVER, BC / ACCESSWIRE / January 22, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the “Company” or “Havn Life”) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it will be included in the First Psychedelics Exchange Traded Fund (“ETF”). The ETF will begin […]
EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower“) an integrated healthcare company serving patients through clinics, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA EUA and Health Canada approval, is pleased to announce significant expansion of our KAI Medical Laboratory in Dallas, Texas […]
Psyched Wellness Submits an Application to Register a Trademark for the Company’s Unique Extraction
Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (“Psyched“) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that it has submitted an application with the United States Patent and Trademark Office (USPTO) to register the trademark “AME-1” in connection with the Company’s […]
New Wave Welcomes Iman Nevab, Homeopathic Research Expert to the Scientific Advisory Board
NEW WAVE HOLDINGS CORP. (the “Company” or “New Wave”) (CSE: SPOR) (FWB: 0XM2) (OTCPK: TRMNF) an investment issuer that provides capital and support services, announced its latest addition to the scientific advisory board. New Wave Holdings Corp. announced today the appointment of a new member to their scientific advisory board. Iman Navab will be joining […]
Revive Therapeutics Announces Upsize to Previously Announced Bought Deal Offering
Revive Therapeutics Ltd. (“Revive“) (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into an amended agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the “Underwriters“), to […]
Psyence Group Inc Completes Reverse Takeover Transaction and Completes Non-brokered Financing
Psyence Group Inc. (“Psyence“), formerly Cardinal Capital Partners Inc., is pleased to announce the successful completion of the previously announced reverse takeover transaction (“RTO“). The Company also is pleased to announce that, in connection with the RTO, MindHealth Biomed Corp. completed its current non-brokered private placement in the amount of $2,179,632.00. Combined with its previous […]
Pure Extracts Closes Upsized $8.5 Million Offering With Strong Retail Demand
VANCOUVER, British Columbia, Jan. 21, 2021 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp. (“Pure” or the “Company”) (CSE: PULL)(XFRA: A2QJAJ) is pleased to announce that it has completed the second and final tranche of its non-brokered private placement offering of special warrants (each, a “Special Warrant”) at $0.505 per Special Warrant, previously announced on December 16, 2020 […]
MINDCURE Included in First Psychedelic ETF & North American Psychedelics Index
Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) is pleased to announce its inclusion among 17 psychedelic companies in the first ever Psychedelic ETF. Horizon’s Psychedelic ETF, is expected to commence trading Jan. 26, 2021 under ticker PSYK on the NEO exchange. The ETF includes companies in the Canadian […]
Der Psychedelika-Markt wird oft mit Wörtern, wie “aufstrebend”, “aufkeimend” und ähnlichen beschrieben, und obwohl dies sicherlich weitgehend zutrifft, sollten Anleger keinen Moment denken, dass dies alles neu ist. Das Gegenteil ist der Fall. Es gibt eine Vielzahl klinischer und präklinischer Daten, die vor dem Inkrafttreten des Gesetzes über kontrollierte Substanzen im Jahr 1970 gesammelt wurden. […]
VANCOUVER, BC, Jan. 20, 2021 /CNW/ – Delic Holdings Corp. (“DELIC” or the “Company“) (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness-focused company, is pleased to announce that its common shares are now trading on the OTCQB Venture Market under the symbol OTC: DELCF. The OTCQB Venture Market is the premiere marketplace for early stage and developing U.S. and […]
Delic Looks to Build a Sprawling ‘Psychedelic Ecosystem’
There have been a number of high profile initial public offerings in the psychedelic space, including COMPASS Pathways’ (NASDAQ: CMPS) $2 billion debut. While there are now more than 30 publicly traded companies in the space, there are thousands more private companies at various stages of funding and development. Delic Corp. (CSE: DELC) (OTCQB: DELCF) […]
MagicMed: Bringing the Drug Candidate Library Model to Psychedelics
The psychedelics market is often described as “emerging”, “burgeoning”, and other similar words, and while certainly true to a large extent, investors shouldn’t think for a moment this is all new. It’s far from it. There are scores of clinical and preclinical data to leverage, most collected before the Controlled Substance Act was enacted in […]
Tryp Therapeutics Invited to Present at “Investing in Psychedelics” Conference
Tryp Therapeutics (CSE: TRYP), a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, has been invited to present at the upcoming Investing in Psychedelics Conference hosted by The CSE (Canadian Securities Exchange). Investing in Psychedelics Conference: Date: Wednesday, January 20th, 2021 Registration: https://promo.cfnmedia.com/psychedelics “We look forward […]
EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower“) an integrated healthcare company serving patients through medical clinics in USA and Canada, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA EUA and Health Canada approval, is pleased to announce its first ever […]
Former LifeLabs COO Joins Novamind Leadership Team
Novamind Inc., (CSE:NM) (“Novamind”) a mental health company specialized in psychedelic medicine, announces the expansion of its leadership team with the appointment of Pierre Bou-Mansour, P.Eng., to the role of Chief Operating Officer. Effective immediately, Mr. Bou-Mansour will assume responsibility for ensuring operational excellence as Novamind develops its network of clinics, retreats, and research sites […]
Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that PharmaTher has entered into an Exclusive Worldwide License Agreement (the “Agreement”) with the National Health Research Institutes (“NHRI”) for the […]
Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (OTC Pink: ENTBF) (“Entheon“), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced a partnership with Divergence Neuro Technologies Inc. (“Divergence”), a company focused on the research and development of a data-driven, cloud-based neuro platform based on electroencephalogram (“EEG“) analysis and machine learning, to research […]
CYBIN Announces Upsize to Previously Announced Bought Deal Offering
Cybin Inc. (NEO: CYBN) (“Cybin“), a life sciences company focused on psychedelic pharmaceutical therapies, is pleased to announce today that, due to strong demand, it has agreed with a syndicate of underwriters led by Canaccord Genuity Corp. (collectively, the “Underwriters“), to increase the size of its previously announced CDN$20,025,000 “bought deal” offering of units. Pursuant […]
Awakn Life Sciences Inc., a biotechnology company focused on research, development and delivery of psychedelic medicines for the treatment of mental health conditions, today announced the appointment of Dr. Shaun McNulty, formerly at GlaxoSmithKline (GSK), as Chief Science Officer and Prof. Celia Morgan, from Exeter University, as Head of Ketamine-Assisted Psychotherapy for the company’s Alcohol […]
Psyched Wellness Announces New OTCQB Ticker: PSYCF
Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (formerly Duncan Park Holdings Corporation) (“Psyched“) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that FINRA accepted its proposed symbol change for the OTCQB market from the former DCNPF to PSYCF. The Company’s shares […]
NeonMind Lists on the Frankfurt Stock Exchange
Vancouver, British Columbia–(Newsfile Corp. – January 19, 2021) – NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) (“NeonMind“), a psychedelic drug development company, is pleased to announce its common shares are now trading on the Frankfurt Stock Exchange (the “FSE“) under the symbol “6FU“. As a result, NeonMind’s common shares are now cross-listed on the Canadian Securities Exchange and the […]
Cybin Announces CDN$20 Million Bought Deal Offering
Cybin Inc. (NEO: CYBN) (“Cybin” or the “Company“), a life sciences company focused on psychedelic pharmaceutical therapies, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. (“Canaccord” or the “Lead Underwriter“) on behalf of a syndicate of underwriters led by Canaccord (together, with the Lead Underwriter, the “Underwriters“), pursuant […]
Lobe Sciences Announces Management Changes and New Director
Lobe Sciences Ltd (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe“) is pleased to announce the appointment of Mr. Philip J. Young as Chief Executive Officer, Corporate Secretary and a director of the Company, effective January 15, 2021. Mr. Young replaces Thomas Baird, who resigned as CEO as of the same date. Philip Young is an accomplished […]
Core One Labs Completes Sale of Non-Core Assets
Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (“Core One“) is pleased to announce that further to its October 30, 2020 press release, the Company has completed the sale of certain of its non-core assets and subsidiaries in California for CAD$3,000,000 plus the assumption of approximately USD$4,000,000 in related liabilities. The completion of this sale […]
Numinus Announces Grant of Stock Options
Numinus Wellness Inc. (“Numinus“) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, announces that it has granted 1,975,000 incentive stock options (the “Options“) to directors, officers and employees of the Company, which are subject to regulatory approval. Of the 1,975,000 […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matthew Nordgren is an ambitious executive, dedicated philanthropist, and accomplished athlete who brings a unique passion to creating strategic alliances. He has breadth and depth of experience in finance, corporate development, and capital sourcing, as well as in building highly motivated teams of skilled professionals. In 2005, Mr. Nordgren received his education at the University […]
In addition to his role as Founder and CEO at MAZAKALI, Sumit is a consultant to The Arcview Group and the Managing Partner of Emerald Ventures. A frequent speaker at investment seminars, Sumit acts as a mentor to Arcview and Canopy companies and serves on the Canopy Investment committee as well as the NCIA Finance […]
Fiore Cannabis (CSE:FIOR) (OTCQX:FIORF) is a publicly-traded company that has been investing in the development of medical and recreational cannabis products since 2014.
WestCann Holdings Ltd. is bringing the industrial and commercial benefits of tobacco processing technologies to the emerging international marijuana and hemp markets.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
